Novo Nordisk Shares Stage Impressive Rebound on Triple Positive News

After experiencing significant declines earlier in the week, Novo Nordisk shares surged dramatically on Thursday, posting gains of up to 5% at one point. This powerful recovery stems from three simultaneous positive developments: the submission of a high-dose Wegovy formulation for U.S. approval, encouraging trial results for an oral weight-loss medication, and more favorable-than-expected Medicare pricing negotiations.

Washington delivered welcome news as the U.S. Centers for Medicare & Medicaid Services and Novo Nordisk established a “Maximum Fair Price” for Ozempic and Wegovy. The agreed price of $274 per month represents a substantial 71% discount from the current list price of approximately $959.

While the discount appears dramatic, market Read more...